Schedule a Demo

Hermes Medical Solutions

HMS

  • Products
    • Enterprise MI
    • SUV SPECT® Reconstruction
    • NM Processing
    • Hybrid3D™ MI Display
    • Oncology & Dosimetry
    • Cardiology
    • Neurology
    • Pulmonary
    • Hybrid3D™ SIRT
  • Partners
    • Professional Associations
    • Corporate Partnerships
    • Educational Partnerships
  • Media
    • Events and Congresses
    • White Papers
    • Press Releases
    • Meet the President
  • Contact
    • Sales
    • Distributors
    • Support and Services
  • About
    • History
    • Careers
    • Management Team
    • Quality Standards

Hybrid Dosimetry™ and OLINDA / EXM® 2.0 Organ Specific Dosing

June 10, 2017 by Benoit Galarneau

Hybrid Dosimetry™ and OLINDA / EXM® 2.0
Organ Specific Dosing

Stockholm - June 10th 2017

Hermes Medical Solutions Launches Hybrid Dosimetry™ and OLINDA / EXM® 2.0 at the annual Society of Nuclear and Molecular Imaging meeting SNMMI taking place in Denver CO, June 10-14th 2017.

Serial radionuclide imaging provides patient specific information for the individual nuclide kinetics in tumors and normal organs to an administered dose. That allows clinicians to personalize further dose to the patient optimizing patient outcome while reducing costs by. Tailoring personalized Targeted Radionuclide Therapy for Peptide Receptor (PRRT) or prostate cancer to absorbed dose limits, requires dosimetry of the highest accuracy.

Hybrid Dosimetry™ and OLINDA / EXM® 2.0*, now integrated, offers a comprehensive dosimetry solution that makes patient imaging easier, more efficient and accurate by eliminating errors associated with manually transferring absorbed dose calculations.

Volume delineation of critical organs such as renal cortex, liver, spleen is time consuming when done manually. It has been reported that severe permanent renal toxicity occurs in 9% of cases as late as 1–10 years after PRRT treatment with 90Y-DOTA-octreotide. Hematological toxicity of equivalent severity was also reported in 10% of patients treated with 177LuDOTA-octreotate**.

The absorbed dose to tumors shows large inter-patient variance and inter-patient variability in kidney dosimetry is too great to justify use of a group-averaged absorbed dose. For patients treated with 177 Lu-DOTA-octreotide, the absorbed dose ranged between 2 and 10 Gy. The absorbed dose to the tumor shows huge inter-patient variance with 177 Lu-DOTA-octreotide and Liver metastases were reported to receive a dose of 167 ± 139 Gy for the first treatment cycle with 7.4 GBq**.

The Hybrid Dosimetry™ solution allows for faster clinical throughput, from imaging to performing MIRD absorbed dose calculations and includes:

  • Hybrid Dosimetry™ for organ delineation and residence time calculation
  • OLINDA / EXM® 2.0 for MIRD based dosimetry

 

*OLINDA/EXM® 2.0 is under review by FDA, 510(k) pending; not available for sale in the United States and no sales orders may be taken. OLINDA/EXM® 2.0 is available in the EU and Canada.

**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991004/pdf/40336_2014_Article_54.pdf

To learn more about the new Dosimetry Solution which is only available from Hermes and how Hermes innovates to bring clinical Dosimetry solutions to the Molecular Imaging field, visit us at booth #201 during the SNMMI meeting June 10th through 14th 2017.

About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.

CONTACT

BENOIT GALARNEAU
Director Strategic Marketing

info@hermesmedical.com
Tel: 1 (514) 288-5675

SCHEDULE YOUR PERSONAL DEMO

Tell us a few things about yourself and we’ll tailor a personal demonstration for you

Sign up for a Demo

Filed Under: Press Releases

Imprint

© 2000–2018
All Rights Reserved

Hermes Medical Solutions
Strandbergsgatan 16
112 51 Stockholm
Sweden

info@hermesmedical.com

Follow us

Regulatory Compliance and Quality

The Quality Management System is certified to the quality standards SS-EN ISO13485:2012 and for products delivered to the Canadian market ISO13485:2003 (CMDCAS).
 

 
 

The system is yearly audited by our notified body Intertek Certification AB. All medical devices delivered on the U.S. market have obtained market clearance from the Food and Drug Administration. All medical devices delivered on the European market conforms to the European Medical Device Directive 93/42/EEC and are handled under Hermes Medical Solutions EC-certificate. All medical devices delivered in Canada conforms to the Canadian medical device regulations (SOR98-282) and are handled under Hermes Medical Device License.

Disclaimer

All information on this website regarding products and services provided by Hermes Medical Solutions (HMS) is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Hermes is not responsible for misprints, out-of-date information, or errors. Hermes makes no warranty, express or implied, or assumes any legal liability or responsibility for the accuracy or completeness of any information contained on this website. Contact your local Hermes Medical Solutions representative to find out more about our offerings in your region.

Legal Information

Privacy Policy
Terms of Use

Share

Copyright © 2018 · Outreach Pro Theme on Genesis Framework · WordPress · Log in